Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1273P is a processed pseudogene originating from the U6 small nuclear RNA gene family[9][1]. Pseudogenes like RNU6-1273P generally arise as genomic relics of retrotransposed RNAs, often mediated by LINE-1 elements[4]. While U6 snRNA itself is an integral part of the spliceosomal complex that processes pre-mRNA, RNU6-1273P does not produce functional RNA and has no confirmed biological or disease-related activity. Pseudogenes are typically characterized by the absence of introns, presence of base mismatches compared to their parent gene, and lack of protein/RNA function[4]. Some pseudogenes are capable of acting as competitive endogenous RNAs (ceRNAs) for microRNA regulation, but no such function has been reported for RNU6-1273P[6][8]. In summary, RNU6-1273P is a nonfunctional pseudogene found in the human genome, not a therapeutic or drug target, and is unrelated to clinical biomarker use or disease mechanisms[9][1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1273, pseudogene (RNU6-1273P).